M2 macrophages injected near injured nerves in mice released natural opioid peptides that significantly reduced mechanical pain sensitivity — an effect reversed by blocking opioid receptors.
Opioid-mediated pain reliefM2 macrophages released Met-enkephalin, dynorphin A, and β-endorphin at nerve injury sites, reducing mechanical pain — an effect completely reversed by the opioid antagonist naloxone methiodide
What the researchers found
M2 macrophages contained and released significantly higher amounts of the opioid peptides Met-enkephalin, dynorphin A (1-17), and β-endorphin compared to unstimulated M0 and pro-inflammatory M1 macrophages.
When 5 × 10⁵ M2 macrophages were injected perineurally at the sciatic nerve injury site on days 14 and 15 after chronic constriction injury, they significantly reduced mechanical hypersensitivity following the second injection. This analgesic effect was reversed by perineurally applied naloxone methiodide (an opioid receptor antagonist that doesn't cross the blood-brain barrier), confirming it was mediated by local opioid receptor activation.
Importantly, M2 cells only reduced mechanical pain — not heat hypersensitivity — and had no effect in sham-operated animals. Neither M0 nor M1 macrophages altered pain sensitivity. Fluorescent tracking showed that transferred cells remained at the nerve and maintained their phenotype.
Why it matters
Neuropathic pain is notoriously difficult to treat, and current opioid medications carry serious risks of addiction and side effects. This study shows that the body's own immune cells can be harnessed to deliver natural opioid peptides directly to the site of nerve injury, potentially offering pain relief without systemic opioid exposure. This cell-based approach could represent a fundamentally different strategy for managing chronic nerve pain.
How the study worked
Mouse bone marrow-derived cells were cultured as M0 (unstimulated), M1 (stimulated with LPS and interferon-γ), or M2 (stimulated with interleukin-4) macrophages. Phenotypes were verified by flow cytometry and cytokine profiling. Opioid peptide levels were measured by radioimmunoassay and enzyme immunoassay. Chronic constriction injury of the sciatic nerve served as the neuropathic pain model. Polarized macrophages (5 × 10⁵ cells) were injected perineurally on days 14 and 15 post-surgery. Pain was assessed with von Frey filaments (mechanical) and Hargreaves test (heat). Fluorescently stained cells were tracked ex vivo to confirm retention and phenotype preservation.
What this study cannot tell us
The study was conducted in mice using a specific nerve injury model, and results may not translate directly to human neuropathic pain conditions. M2 macrophages only reduced mechanical pain, not heat sensitivity, suggesting they address only certain pain modalities. The effect required two injections and was assessed short-term; durability of pain relief is unknown. The feasibility of harvesting, polarizing, and transplanting a patient's own macrophages for clinical use remains to be determined.
How to read the evidence
This is a well-designed preclinical study using multiple controls (M0, M1, sham surgery), pharmacological verification (naloxone reversal), and cell tracking to confirm mechanisms. However, it remains a mouse study and clinical translation has not been tested.
When this study was published
Published in 2016, this study is a foundational contribution to the field of immune cell-mediated analgesia. The concept of using endogenous opioid-producing cells for pain relief continues to be an active area of research.
The bigger picture
This study bridges immunology and pain research by demonstrating that immune cell phenotype determines opioid peptide production. It supports the growing understanding that pain and inflammation are not simply interchangeable — anti-inflammatory M2 macrophages actively produce analgesic molecules. This work aligns with broader research into cell-based therapies and endogenous opioid systems as alternatives to synthetic opioid drugs for chronic pain management.
Questions still open
- Could autologous M2 macrophage transplantation be developed as a clinical treatment for neuropathic pain in humans?
- Why did M2 macrophages reduce mechanical but not heat hypersensitivity — do different opioid peptides modulate different pain modalities?
- Could pharmacological approaches that promote M2 polarization at injury sites achieve similar opioid-mediated pain relief without cell transplantation?
Common questions
What are M2 macrophages and how do they differ from other immune cells?
Could this approach replace opioid painkillers for nerve pain?
Read the original research
Adoptive transfer of M2 macrophages reduces neuropathic pain via opioid peptides.
Journal of neuroinflammation, 13(1), 262
Citation
Pannell, Maria; Labuz, Dominika; Celik, Melih Ö; Keye, Jacqueline; Batra, Arvind; Siegmund, Britta; Machelska, Halina. (2016). Adoptive transfer of M2 macrophages reduces neuropathic pain via opioid peptides.. Journal of neuroinflammation, 13(1), 262.